Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Pacific Biosciences of California Stock Popped Today

By Joe Tenebruso - Feb 10, 2021 at 7:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The gene sequencing company is receiving a $900 million investment from a renowned international conglomerate.

What happened

Shares of Pacific Biosciences of California (PACB 12.75%) surged 16% on Wednesday after the DNA sequencing leader said it obtained a strategic investment from Japanese technology conglomerate SoftBank Group (SFTB.Y 0.88%)

So what

Softbank subsidiary SB Management will purchase $900 million in convertible senior notes that it can convert into PacBio stock at a price of $43.50 per share. The notes mature on Feb. 15, 2028, and pay 1.5% interest annually.

A person points to an upwardly sloping line that's above a flat line.

Shares of Pacific Biosciences rose sharply on Wednesday following its deal with SoftBank. Image source: Getty Images.

PacBio said the cash will help it broaden its product portfolio and fast-track its commercialization plans. "This strategic investment by SoftBank validates our leadership position in the long-read DNA sequencing market and enables us to further accelerate our growth strategies," PacBio CEO Christian Henry said in a press release.

Now what

PacBio is a leader in high-fidelity (HiFi) DNA-sequencing platforms, which produce accurate and complete data that researchers can use to study genetic diseases. The goal is to give doctors a better understanding of how genes contribute to human health, so they can develop more effective treatments for a wide range of genetic disorders. 

"We believe that PacBio's HiFi sequencing will be the de facto standard tool for population genomics fundamentally altering the practice of healthcare," SB Management CEO Akshay Naheta said.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pacific Biosciences of California, Inc. Stock Quote
Pacific Biosciences of California, Inc.
PACB
$6.10 (12.75%) $0.69
SoftBank Group Corp. Stock Quote
SoftBank Group Corp.
SFTB.Y
$21.30 (0.88%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.